MA52483A - Dérivés de gip et leurs utilisations - Google Patents
Dérivés de gip et leurs utilisationsInfo
- Publication number
- MA52483A MA52483A MA052483A MA52483A MA52483A MA 52483 A MA52483 A MA 52483A MA 052483 A MA052483 A MA 052483A MA 52483 A MA52483 A MA 52483A MA 52483 A MA52483 A MA 52483A
- Authority
- MA
- Morocco
- Prior art keywords
- gip derivatives
- gip
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666916P | 2018-05-04 | 2018-05-04 | |
| EP18172827 | 2018-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52483A true MA52483A (fr) | 2021-03-10 |
Family
ID=66440040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052483A MA52483A (fr) | 2018-05-04 | 2019-05-03 | Dérivés de gip et leurs utilisations |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11633459B2 (fr) |
| EP (1) | EP3788063B1 (fr) |
| JP (2) | JP6818940B2 (fr) |
| KR (1) | KR102379958B1 (fr) |
| CN (1) | CN112074531B (fr) |
| AU (1) | AU2019263674B2 (fr) |
| BR (1) | BR112020022027A2 (fr) |
| CA (1) | CA3097939A1 (fr) |
| CL (1) | CL2020002796A1 (fr) |
| CO (1) | CO2020014180A2 (fr) |
| ES (1) | ES2961384T3 (fr) |
| IL (1) | IL278171A (fr) |
| MA (1) | MA52483A (fr) |
| MX (1) | MX2020011427A (fr) |
| PE (1) | PE20210473A1 (fr) |
| PH (1) | PH12020551742A1 (fr) |
| RU (1) | RU2020136305A (fr) |
| SG (1) | SG11202010297UA (fr) |
| TW (1) | TWI707865B (fr) |
| WO (1) | WO2019211451A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI771319B (zh) | 2016-09-09 | 2022-07-21 | 美商英塞特公司 | 吡唑并吡啶化合物及其用途 |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| WO2018049214A1 (fr) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| US10800761B2 (en) | 2018-02-20 | 2020-10-13 | Incyte Corporation | Carboxamide compounds and uses thereof |
| WO2019164847A1 (fr) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Composés d'indazole et leurs utilisations |
| TWI707865B (zh) * | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| PE20221419A1 (es) | 2019-08-06 | 2022-09-20 | Incyte Corp | Formas solidas de un inhibidor de hpk1 |
| JP7415022B2 (ja) * | 2020-02-05 | 2024-01-16 | イーライ リリー アンド カンパニー | 三連樹脂反応器ペプチド合成機 |
| JP7544838B2 (ja) | 2020-03-06 | 2024-09-03 | サノフイ | 選択的ｇｉｐ受容体アゴニストとしてのペプチド |
| JP7736315B2 (ja) * | 2020-03-31 | 2025-09-09 | アンタロス メディカル アクティエボラーグ | イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CA3184717A1 (fr) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Co-agonistes au niveau des recepteurs de glp-1 et de gip appropries pour une administration par voie orale |
| MX2023005408A (es) * | 2020-11-09 | 2023-07-25 | Embark Biotech Aps | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. |
| KR102815534B1 (ko) | 2021-06-23 | 2025-06-02 | 주식회사 펩트론 | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 |
| CA3230915A1 (fr) | 2021-09-06 | 2023-03-09 | Thomas Boehme | Nouveaux peptides utilises en tant qu'agonistes puissants et selectifs du recepteur de gip |
| WO2023118263A1 (fr) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonistes pour le traitement d'un trouble de l'alimentation |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023151594A1 (fr) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | Composition comprenant des agonistes du récepteur gip et des agonistes du récepteur glp-1 et son utilisation |
| KR20240095076A (ko) | 2022-12-16 | 2024-06-25 | 주식회사 펩트론 | Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| GB202302686D0 (en) * | 2023-02-24 | 2023-04-12 | Imperial College Innovations Ltd | Novel compounds |
| JP2026507088A (ja) * | 2023-02-24 | 2026-02-27 | アイピー２アイピーオー イノベ－ションズ リミテッド | 化合物 |
| CN120659805A (zh) * | 2023-10-31 | 2025-09-16 | 深圳信立泰药业股份有限公司 | Glp-1化合物及其制备方法与应用 |
| CN120349392A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种gip激动剂化合物 |
| WO2025176999A2 (fr) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Nouveaux composés |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921748B1 (en) * | 1999-03-29 | 2005-07-26 | Uutech Limited | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| EP2328922A4 (fr) | 2008-08-07 | 2013-01-02 | Ipsen Pharma Sas | Analogues de polypeptide insulinotrope glucose-dépendant |
| CA2733005C (fr) | 2008-08-07 | 2016-09-27 | Ipsen Pharma S.A.S. | Analogues tronques de polypeptide insulinotrope glucose-dependant |
| BRPI0917580A2 (pt) * | 2008-08-07 | 2016-10-11 | Ipsen Pharma Sas | composto, composição farmacêutica, métodos para elicitar um efeito agonista e antagonista de um receptor de gip, para tratar condições ou doenças mediadas por ligação de receptor de gip, para tratar diabetes, para tratar distúrbios relacionados com diabete, para tratar ou previnir causas secundárias de diabete para tratar obesidade, e para estimular secreção de insulina, e, uso de um análogo de peptídeo |
| KR20130133104A (ko) | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체 |
| CN104327182B (zh) | 2009-12-16 | 2020-04-17 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
| RU2012136450A (ru) | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
| US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
| EP2569000B1 (fr) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone |
| US9249181B2 (en) * | 2010-09-13 | 2016-02-02 | Amylin Pharmaceuticals, Llc | C-terminal amidation of polypeptides |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| SG191252A1 (en) * | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| WO2012167744A1 (fr) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation |
| US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| WO2013164483A1 (fr) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Composés agonistes doubles du gip-glp-1 et méthodes |
| RU2015101697A (ru) * | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| JP6300239B2 (ja) * | 2012-06-21 | 2018-03-28 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| WO2014158900A1 (fr) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Conjugués d'insuline-incrétine |
| PL2986313T3 (pl) | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
| LT3004155T (lt) * | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| US10266577B2 (en) | 2013-08-15 | 2019-04-23 | Novo Nordisk A/S | GLP-1 derivatives, and uses thereof |
| WO2015022420A1 (fr) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète |
| US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| EP3151852A1 (fr) * | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Co-agonistes de récepteur du glucagon/glp-1 à usage médical |
| EP3189072B1 (fr) | 2014-09-05 | 2018-07-18 | University of Copenhagen | Peptides analogues du gip |
| TWI705973B (zh) * | 2014-10-29 | 2020-10-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ促效劑化合物及方法 |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| JP2018506571A (ja) | 2015-02-27 | 2018-03-08 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物 |
| WO2016205488A1 (fr) | 2015-06-17 | 2016-12-22 | The California Institute For Biomedical Research | Agents thérapeutiques modifiés et compositions associées |
| WO2017160669A1 (fr) | 2016-03-18 | 2017-09-21 | Merck Sharp & Dohme Corp. | Conjugués d'insuline-incrétine |
| WO2017210168A1 (fr) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Agonistes hydrosolubles et chimiquement stables du depsi-glucagon |
| BR112019025195A8 (pt) * | 2017-05-31 | 2020-07-07 | Univ Copenhagen | análogos do peptídeo gip de ação prolongada |
| TWI707865B (zh) * | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
-
2019
- 2019-05-03 TW TW108115352A patent/TWI707865B/zh not_active IP Right Cessation
- 2019-05-03 ES ES19722582T patent/ES2961384T3/es active Active
- 2019-05-03 PE PE2020001751A patent/PE20210473A1/es unknown
- 2019-05-03 JP JP2020512588A patent/JP6818940B2/ja active Active
- 2019-05-03 KR KR1020207034171A patent/KR102379958B1/ko not_active Expired - Fee Related
- 2019-05-03 EP EP19722582.4A patent/EP3788063B1/fr active Active
- 2019-05-03 BR BR112020022027-2A patent/BR112020022027A2/pt not_active Application Discontinuation
- 2019-05-03 AU AU2019263674A patent/AU2019263674B2/en not_active Ceased
- 2019-05-03 US US17/052,702 patent/US11633459B2/en active Active
- 2019-05-03 CN CN201980029824.2A patent/CN112074531B/zh active Active
- 2019-05-03 MA MA052483A patent/MA52483A/fr unknown
- 2019-05-03 RU RU2020136305A patent/RU2020136305A/ru unknown
- 2019-05-03 MX MX2020011427A patent/MX2020011427A/es unknown
- 2019-05-03 WO PCT/EP2019/061413 patent/WO2019211451A1/fr not_active Ceased
- 2019-05-03 SG SG11202010297UA patent/SG11202010297UA/en unknown
- 2019-05-03 CA CA3097939A patent/CA3097939A1/fr not_active Withdrawn
- 2019-05-03 US US16/403,241 patent/US10604555B2/en active Active
-
2020
- 2020-04-09 JP JP2020070421A patent/JP2020125311A/ja not_active Withdrawn
- 2020-10-20 PH PH12020551742A patent/PH12020551742A1/en unknown
- 2020-10-20 IL IL278171A patent/IL278171A/en unknown
- 2020-10-28 CL CL2020002796A patent/CL2020002796A1/es unknown
- 2020-11-12 CO CONC2020/0014180A patent/CO2020014180A2/es unknown
-
2023
- 2023-02-03 US US18/105,419 patent/US20240190938A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020014180A2 (es) | 2021-01-29 |
| KR20210005700A (ko) | 2021-01-14 |
| RU2020136305A (ru) | 2022-05-05 |
| BR112020022027A2 (pt) | 2021-02-02 |
| KR102379958B1 (ko) | 2022-04-01 |
| ES2961384T3 (es) | 2024-03-11 |
| US11633459B2 (en) | 2023-04-25 |
| EP3788063A1 (fr) | 2021-03-10 |
| AU2019263674A1 (en) | 2020-11-26 |
| SG11202010297UA (en) | 2020-11-27 |
| CN112074531A (zh) | 2020-12-11 |
| JP6818940B2 (ja) | 2021-01-27 |
| CL2020002796A1 (es) | 2021-02-19 |
| PE20210473A1 (es) | 2021-03-08 |
| TWI707865B (zh) | 2020-10-21 |
| US10604555B2 (en) | 2020-03-31 |
| TW202003550A (zh) | 2020-01-16 |
| EP3788063C0 (fr) | 2023-08-09 |
| IL278171A (en) | 2020-11-30 |
| JP2020528925A (ja) | 2020-10-01 |
| JP2020125311A (ja) | 2020-08-20 |
| WO2019211451A1 (fr) | 2019-11-07 |
| PH12020551742A1 (en) | 2021-06-28 |
| MX2020011427A (es) | 2020-12-07 |
| US20220000982A1 (en) | 2022-01-06 |
| AU2019263674B2 (en) | 2023-03-02 |
| EP3788063B1 (fr) | 2023-08-09 |
| CA3097939A1 (fr) | 2019-11-07 |
| US20190367578A1 (en) | 2019-12-05 |
| CN112074531B (zh) | 2025-04-15 |
| US20240190938A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52483A (fr) | Dérivés de gip et leurs utilisations | |
| EP3706762A4 (fr) | N4-hydroxycytidine et dérivés et leurs utilisations anti-virales | |
| EP3841096A4 (fr) | Dérivés de pyridinylméthylènepipéridine et leurs utilisations | |
| EP3917529A4 (fr) | Composés et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3829649A4 (fr) | Complexes de ciblage musculaire et leurs utilisations | |
| EP3787607A4 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| EP3849983A4 (fr) | Composés de triazolo-pyrimidine et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3917527A4 (fr) | Composés et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| EP3768269A4 (fr) | Composés et leurs utilisations | |
| MA55385A (fr) | Composés et leurs utilisations | |
| EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
| EP3697410A4 (fr) | Dérivés de benzimidazole et leurs utilisations | |
| EP3790883A4 (fr) | Composés hétéroaryles et leurs utilisations | |
| EP4017843A4 (fr) | Dérivés de benzènesulfonamide et leurs utilisations | |
| EP3526215A4 (fr) | Dérivés de n-acyléthanolamide et leurs utilisations | |
| EP3853216A4 (fr) | Composés substitués par pyridinyle et leurs utilisations | |
| EP3838900A4 (fr) | Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées | |
| EP3323817A4 (fr) | Dérivés d'aniline pyrimidine et leurs utilisations | |
| MA52411A (fr) | Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales | |
| EP3303366A4 (fr) | Dérivés de dolastatine 10 et utilisations de ceux-ci | |
| MA52976A (fr) | Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations |